FANCM pathogenic variants were shown to be associated with a moderate risk of developing high-grade serous epithelial ovarian cancer, but p.Arg1931* appeared to confer a lower risk.18 Moreover, five female breast cancer probands carrying homozygous FANCM truncating variants were recently described.9 Three of these, two homozygous for p.Gln1701*, and one for p.Arg1931*, developed breast cancer at age 52 years or later and their cells did not demonstrate chromosome fragility. The gene discussed is FANCM; the disease is breast carcinoma.